Safety of conjugated linoleic acid (CLA) in overweight or obese human volunteers

The main objective of the study was to investigate the safety of conjugated linoleic acid (CLA) in healthy volunteers. The effect of CLA on body compo sition was also investigated. The trial design was a randomized, double-blind placebo controlled study in cluding 60 overweight or obese volunteers (body mass index (BMI) 27.5-39.0 kg/m(2)). The subjects were divided into two groups receiving 3.4 g CLA or placebo (4.5 g olive oil) daily for 12 weeks. The safety was evaluated by a nalysis of blood parameters and by clinical examinations at baseline and we ek 12. Vital signs and adverse events were registered at baseline, week 6, and week 12. Bio Impedance Assessment was applied for body composition meas urements. 55 subjects completed the study. Adverse events occurred in 10% of the subj ects. No difference in adverse events or other safety parameters was found between the treatment groups. Small changes in the laboratory safety data w ere not regarded as clinically significant. Moreover, no clinically signifi cant changes in vital signs were observed in any of the groups. In the CLA group, mean weight was reduced by 1.1 kg (paired t-test p = 0.00 5), while mean BMI was reduced by 0.4 kg/m(2) (p = 0.007). However, the ove rall treatment effect of CLA on body weight and BMI was not significant. Th ere were no differences found between the groups with regard to efficacy pa rameters. The results indicate that CLA in the given dose is a safe substance in heal thy populations with regard to the safety parameters investigated.